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Enteral Tube Feeding in Paediatric 
Mitochondrial Diseases
Han Som Choi & Young-Mock Lee
We investigated the effects of enteral tube feeding in Korean children with mitochondrial diseases. 
We performed a retrospective chart review of 68 paediatric patients with mitochondrial diseases on 
enteral tube feeding at a tertiary referral centre. The outcome of enteral nutrition was evaluated by 
decrease in gastrointestinal (GI) symptoms, weight gain, and increase in developmental quotient (DQ) 
among patients with data available. Among 68 patients, 56 (82%) were on gastrostomy and 12 (18%) 
were on prolonged nasogastric (NG) tube feeding. Decrease of GI symptoms was present in 37 of 48 
patients (77%). Weight gain was present in 18 of 64 patients (28%) and was more prominent in the 
gastrostomy group (n = 17/54, 32%). Increase in DQ was similar between the NG tube and gastrostomy 
groups (total n = 10/48, 21%). Complications occurred in 42% (n = 5/12) of the NG tube group and 64% 
(n = 36/56) of the gastrostomy group. They varied in range, from mild to severe. Most complications 
were minor; there were 5 cases (9%) requiring gastrostomy removal or additional procedure and 2 cases 
(4%) of gastrostomy-related morbidity. Our results show that in paediatric patients with mitochondrial 
diseases, enteral tube feeding could help enhance quality of life by relieving GI symptoms, ameliorate 
growth failure and enhance development.
Mitochondria are the hub of numerous metabolic pathways, including pyruvate oxidation, metabolism of basic nutri-
ents, and generation of adenosine triphosphate (ATP)1. Disorders in any of these pathways cause mitochondrial dis-
eases1. Studies have focused on defects in the respiratory chain complex, the major site of ATP production, due to its 
crucial role in life maintenance1,2. Defective ATP metabolism leads to insufficient energy supply, thus mitochondrial 
diseases mainly involve organs with relatively higher energy requirements, such as the brain, heart, and muscles2.
Mitochondrial diseases are prevalent in 10 to 15 cases per 100,000 persons1. They are heterogeneous and 
include diverse syndromes, but the most common manifestation is non-specific2. Neurodevelopmental regression 
and neurologic symptoms are key indicators of the diseases2. A study of 73 paediatric patients with the diseases 
showed 90% neurologic involvement during the median 12-year follow-up period and mortality rate of 46%3.
As mitochondrial diseases involve multiple organs, gastrointestinal (GI) involvement or nutritional deficit is 
common. GI involvement is reportedly present in 29%3 and 48%4 of patients with mitochondrial diseases, and 
failure to thrive is reportedly present in 52%3,4. Major GI symptoms include persistent vomiting, failure to thrive, 
and dysphagia2. Swallowing difficulties could inhibit sufficient oral intake and may result in aspiration or chest 
infection5. Failure to thrive and inadequate oral intake could inhibit long-term growth and nutrition5.
Enteral tube feeding is indicated in patients with neurologic diseases6. Nasogastric (NG) tube feeding is useful 
for 1 to 3 months, and gastrostomy is the appropriate option if feeding problems persist7. Research shows that 
gastrostomy benefits paediatric patients with neurodevelopmental diseases in terms of clinical progress and qual-
ity of life5. Complication rates of enteral tube feeding reportedly range from 10%8 to 80%9, with 5%8 to 20%9 of 
patients developing major complications.
As gastrostomy shows promising outcomes in the nutrition of neurologic patients, researchers have evaluated 
its effect in neurologic diseases such as cerebral palsy or Rett syndrome10,11. We have found no previous research 
on enteral tube feeding in patients with mitochondrial diseases. In this study, we report indications and outcomes 
of enteral feeding in 68 paediatric patients with mitochondrial diseases.
Materials and Methods
Patient selection and diagnostic evaluation. We performed a retrospective chart review of paediatric 
patients diagnosed with mitochondrial diseases in Gangnam Severance hospital, a tertiary medical referral centre 
in Seoul, Korea. Of 372 patients diagnosed with mitochondrial diseases, 68 patients began enteral tube feeding 
from July 2005 to June 2016.
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Clinical characteristics of the patients were analysed by gender, disease onset, systemic involvement, and dis-
ease progress. Laboratory test results were obtained, including serum lactic acid. Muscle biopsies were performed 
surgically from the quadriceps muscle, and routine histological, immunohistochemical, and electron microscopic 
exams were conducted. Biochemical assays to evaluate mitochondrial respiratory chain enzyme activity were 
also performed, defining the enzyme to be defective when residual enzyme activity was below 10% of reference. 
Diagnosis of mitochondrial diseases was made based on biochemical, pathological, and clinical data as suggested 
by Bernier et al.12. The clinical diagnosis of syndromes was confirmed at an outpatient clinic or during admission. 
All procedures conducted were approved by the institutional review board of Gangnam Severance Hospital in 
Seoul, Korea. Informed consent were obtained and all methods were performed in accordance with the relevant 
guidelines and regulations of the board.
Enteral tube feeding. We reviewed the patients’ age at the beginning of enteral tube feeding, interval 
between the onset of the disease and the start of enteral tube feeding, and GI symptoms leading to enteral tube 
feeding. Enteral tube feeding specified the use of NG tube or gastrostomy for nutritional support beyond the 
oesophagus, excluding oral nutritional supplements in enteral nutrition6. No patient in our study was on oral 
supplement. Prolonged NG feeding was defined as NG tube feeding for over four weeks due to GI symptoms 
related to the patients’ diseases. Patients who received tube feeding due to transient decline in general condition 
were excluded. Gastrostomy included percutaneous endoscopic gastrostomy (PEG) and surgical gastrostomy, 
either by laparoscopy or open surgery.
We discussed all the patients’ nutrition plan with the nutrition support team in the hospital. Patients fed on 
standard enteral formula with energy density approximating 1 kcal/ml. The composition of fat, carbohydrate and 
protein was not altered. As recent data supports bolus feeding as physiologic and standard6, we set all patients’ 
feeding end point as bolus feeding. Some patients went through transient continuous feeding for adaptation to 
enteral tube feeding, but all settled with bolus feeding.
Assessment of outcomes and complications. Outcomes of enteral nutrition were evaluated by decrease 
in GI symptoms, weight gain, and increase in developmental quotients (DQ) among patients with data availa-
ble. GI symptoms reflect the indications, or initiative causes, of enteral tube feeding. Weight gain represents the 
physical and nutritional effect of enteral tube feeding. DQ shows the developmental and systemic effect of enteral 
tube feeding. Progress of symptoms was assessed by chart review. We confirmed the patients’ decrease in GI 
symptoms if the patients or guardians reported decreased symptoms for at least two consecutive hospital visits 
following the start of enteral tube feeding. Patients’ weight was measured at each hospital visit in kilograms and 
converted to z-scores according to the Korean national growth chart13. We defined ‘weight gain’ as an increase 
in z-score after one year from the start of enteral tube feeding. DQ was evaluated by the Korean Infant and Child 
Developmental Test (KICDT)14 at every admission. It assesses five categories of gross motor, fine motor, language, 
cognitive-adaptive, and social-personal skills. We defined ‘increase in DQ’ as the increase in DQ at least three 
months after the initiation of enteral tube feeding.
We examined complications of enteral tube feeding with patients divided into NG tube and gastrostomy 
groups. Chart review revealed minor complications, such as abdominal pain and gastrostomy site granulations, 
and major complications involving gastrostomy removal or morbidity related to gastrostomy.
For statistical analysis of outcomes, we used SPSS version 23.0 (SPSS Inc., Chicago, IL, USA).
Results
Patient characteristics. Sixty-eight patients up to age 18 years old were diagnosed with mitochondrial dis-
eases and started enteral tube feeding from July 2005 to June 2016 (Table 1). Mean age at the onset of first clinical 
symptom was 1.6 years old. Organ involvement was evaluated at the last hospital visit. Multi-organ involvement 
was diagnosed in all patients. Neurologic and GI symptoms were evident in all patients, and pulmonary and mus-
cular involvement were common. Functional capacity of patients at their final visit during the study period was 
overall poor, with 51 patients (75%) bedridden and 15 patients (22%) expired. Forty-eight patients (70%) showed 
clinical regression during repeated hospital visits.
Diagnostic evaluation of mitochondrial diseases. Patients went through multiple diagnostic studies 
for mitochondrial diseases (Table 2). Over half of patients showed non-specific features of mitochondrial dis-
eases (52%). Thirty-three patients had syndromes compatible with mitochondrial diseases. Leigh’s syndrome was 
most common (41%), followed by mitochondrial encephalomyopathy, lactic acidosis, and stroke-like episodes 
(MELAS) (6%) and myoclonic epilepsy with ragged-red fibres (MERRF) (1%).
Lactic acidosis was present in 39 patients (57%). Among 60 patients who underwent mitochondrial respira-
tory chain (MRC) complex evaluation, 51 patients had MRC defects (85%). MRC I defect was the most com-
mon manifestation (45 patients, 75%). Sixty-two patients underwent muscle biopsy analysed by microscopy; 
13 patients (21%) showed ragged red fibres on light microscopy, a specific finding for mitochondrial diseases. 
Pleoconia and megaconia were evident in 24 and 25 patients each, respectively (39% and 40%).
Gastrointestinal symptoms and indications for enteral tube feeding. Mean age of patients at the start 
of enteral tube feeding was 5.8 years, ranging from 0.5 to 18.5 years (Table 3). Mean duration from the first symptom 
of mitochondrial disease to enteral tube feeding was 4.6 years (range, 0–17.3 years). The majority of patients had GI 
symptoms requiring enteral tube feeding. The most common indication was oropharyngeal dysphagia, which was 
apparent in 55 patients (81%), followed by weight decrease in 43 patients (63%). Forty-nine patients were evaluated 
for gastroesophageal reflux (GER), among whom 36 underwent both oesophagography and 24-hour pH monitor-
ing. While 39 of 49 patients had positive results in either study (80%), 24 hr pH monitoring rendered more positive 
results (33/39 examinees, 85%) than contrast oesophagography (18/46 examinees, 39%).
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As for the type of enteral tube feeding, 56 patients underwent surgical or percutaneous endoscopic gastros-
tomy (82%), and the other 12 patients were on prolonged nasogastric tube feeding (18%).
Outcomes of enteral tube feeding. Effects of enteral tube feeding were analysed in patients with 
follow-up data available. Each outcome was compared among patients with NG tube versus gastrostomy (Table 4). 
Alleviation of GI symptoms was the most common effect of enteral tube feeding (37/48, 77%), evident in over 
70% of both NG tube (6/7, 86%) and gastrostomy (31/41, 76%) patients.
Weight gain was present in 18 of 65 patients (28%). The gastrostomy group had more patients with increased 
weight z-score after enteral tube feeding (17/55, 31%) compared to the NG tube group (1/10, 10%).
Increase in DQ was evident in 10 patients. No significant difference was found between NG tube (1/4, 25%) 
and gastrostomy (9/44, 21%) patients.
There was no statistically meaningful difference between the NG tube and gastrostomy groups regarding the 
three outcomes.
Patient characteristics No. of patients (%)
Male: Female 29 (43): 39 (57)
Age at onset of first symptom, years 1.6 (0–15.5)*
Organ involvement (n, %)
          Central/Peripheral neurologic system 68 (100)
          Gastrointestinal 68 (100)
          Pulmonary 51 (75)
          Muscular 35 (52)
          Cardiac 11 (16)
          Endocrinologic 9 (13)
          Otologic 9 (13)
          Ophthalmologic 8 (12)
          Nephrologic 8 (12)
          Haematologic 2 (3)
Functional capacity (n, %)
          Ambulatory 1 (1.5)
          Wheelchair bound 1 (1.5)
          Bedridden 51 (75)
          Expired 15 (22)
Table 1. Subject demographics (n = 68). *Data is given as mean value (range).
Diagnostic criteria
No. of patients 
(%)
Syndrome
          Leigh’s syndrome 28 (41)
          MELAS 4 (6)
          MERRF 1 (1)
          Non-specific mitochondrial diseases 35 (52)
Lactic acidosis 39 (57)
Mitochondrial respiratory chain (MRC) defects (n = 60)
          MRC I 45/60 (75)
          MRC II 1/60 (2)
          MRC IV 5/60 (8)
Microscopic pathology (n = 62)
Light microscopy
           Mitochondrial-disease specific 13/62 (21)
           Nonspecific for mitochondrial disease 7/62 (11)
Electron microscopy
           Pleoconia 24/62 (39)
           Megaconia 25/62 (40)
Table 2. Diagnostic evaluation of mitochondrial disease in study population (n = 68). MELAS: mitochondrial 
encephalomyopathy, lactic acidosis, and stroke-like episodes. MERRF: myoclonic epilepsy with ragged-red fibers.
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Complications of enteral tube feeding. Forty-one of 68 patients (60%) had complications related to 
enteral tube feeding. (Table 5) Five of 12 NG tube patients (42%) had adverse effects, including haemorrhage 
related to NG tube placement (3/12, 25%) and mechanical tube problems (2/12, 17%). Thirty-six of 56 gastros-
tomy patients (64%) had complications, most commonly gastrostomy site granulation (19/56, 34%) and gas-
trostomy site leakage (10/56, 18%). Complications requiring removal of gastrostomy or additional gastrostomy 
occurred in 5 of 56 patients (9%). Two patients (4%) had morbid complications clinically related to gastrostomy.
Discussion
This study is the first survey of enteral tube feeding among paediatric patients with mitochondrial diseases. A 
few studies evaluating enteral tube feeding have included neuromuscular diseases5,11,15–18, but no study focused 
solely on mitochondrial diseases. As with a previous investigation including 73 patients3, mitochondrial disease 
patients in our study showed multi-organ involvement and severe clinical progress. As there is no cure available, 
supportive care is the mainstay of management in this patient group2. Thus GI support is needed as an important 
component of systemic management.
Our patients had multiple GI symptoms leading to enteral tube feeding. Previous studies pointed to swal-
lowing difficulty or nutritional deficit resulting in weight loss as the major indication for PEG5,7,17. In our study, 
symptoms of swallowing difficulty including oropharyngeal dysphagia, vomiting, and aspiration, and decrease in 
weight occurred in the majority of patients leading to enteral tube feeding.
Outcomes of enteral tube feeding were decrease in GI symptoms, weight gain, and increase in DQ. In a study 
of patients with Rett syndrome, caregivers found decrease in vomiting or choking after gastrostomy11. In a study 
of 10 patients, decrease in GER was found after PEG insertion19. In our study, a significant percentage of patients 
in both the NG tube and gastrostomy groups showed a decrease in GI symptoms. Weight gain was prominent in 
both groups, with a higher percentage of patients showing weight gain in the gastrostomy group. Maintenance of 
weight gain has been reported in other studies investigating children with neuromuscular disorders, both with 
PEG and surgical gastrostomy5,16. The relative superiority of weight gain in the gastrostomy group is consistent 
with a recent study of 166 paediatric patients9, where fewer patients in the gastrostomy group remained under-
weight one year after tube feeding compared to the NG tube group. There was no statistical difference between the 
NG tube group and gastrostomy group in the two outcomes. As nutritional support is critical in the conservative 
No. of patients (%)
Age at the start of enteral tube feeding, years 5.8 (0.5–18.5)a
Time from the first symptom to enteral tube 
feeding, years 4.6 (0–17.3)
a
Gastrointestinal symptoms (multiple indications)
        Oropharyngeal dysphagia 55 (81)
        Weight decrease 43 (63)
        Recurrent vomiting 42 (62)
        Aspiration 40 (59)
        Gastrointestinal haemorrhage 29 (43)
        Regurgitation 22 (32)
        Constipation 10 (15)
GER confirmed by imaging studiesb 39/49 (80)
        Contrast oesophagography 18/46 (39)
        24 hr pH monitoring 33/39 (85)
Type of enteral tube feeding
        Gastrostomy 56 (82)
        Prolonged nasogastric tube feeding 12 (18)
Table 3. Gastrointestinal symptoms and indications for enteral tube feeding (n = 68). aData is given as mean 
value (range). bOut of 49 patients who went through any of the imaging evaluation for GER, 36 patients 
underwent both. GER: gastroesophageal reflux.
Enteral tube 
feeding
Decrease in GI 
symptoms (n = 48)
Weight gain 
(n = 64)
Increase in 
DQ (n = 48)
    NG tube 6/7 (86) 1/10 (10) 1/4 (25)
    Gastrostomy 31/41 (76) 17/54 (32) 9/44 (21)
Total 37/48 (77) 18/64 (28) 10/48 (21)
Table 4. Outcomes of enteral tube feeding according to feeding type (n = 68) (No. of patients, %). Decrease in 
GI symptoms: decreased symptoms for at least two consecutive hospital visits following the start of enteral tube 
feeding Weight gain: increase in z-score in 1 year after the start of enteral tube feeding Increase in DQ: increase 
of DQ after at least 3 months since the start of enteral tube feeding.
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care of incurable diseases and gastrostomy is relatively superior in providing nutritional improvement compared 
to NG tube, prompt gastrostomy could aid in the treatment of patients with mitochondrial diseases.
Developmental delay is a prominent feature of mitochondrial diseases, reported to be present in 68% to 85% 
of patients3,4,20. Yet there is no report on developmental outcomes as related to enteral tube feeding in this patient 
group. We noted positive short term outcomes with enteral tube feeding in terms of development. Long term 
studies would confirm whether enteral feeding could overcome the developmental regression reported to be 
present in 60% of patients with these diseases21.
The patients started enteral tube feeding 4.6 years in average after they had first symptoms of mitochondrial 
diseases. The majority of them had multiple GI symptoms, and we could not specify when each GI symptom 
appeared in this retrospective study. If the patients went through earlier evaluation and started enteral tube feed-
ing before GI symptoms or growth failure aggravated, the results could have been more positive towards allevia-
tion of GI symptoms, prevention of growth failure or deterioration of development.
A previously reported complication rate of NG tube was 46%9, consistent with our NG tube group (42%). The 
complication rate of gastrostomy feeding differs significantly among studies, ranging from 10%8 to 80%, with 
most complications being minor; 20% of patients reportedly develop major complications without morbidity9. 
Another recent study reported a 76% complication rate with 15% major complications16. In our study, 36 of 56 
patients with gastrostomy (64%) had complications. While most patients had minor complications, there were 5 
patients requiring removal of existing gastrostomy or additional procedure and 2 patients with morbidity related 
to the gastrostomy (13%). Despite severe disease progression and multi-organ involvement, the complication rate 
of our patients was compatible with previous studies on enteral tube feeding. As modification of feeding could 
efficiently enhance nutrition, gastrostomy could be a reasonable option for nutritional support in patients with 
mitochondrial diseases.
There are limitations to our study. This is a retrospective study with uncontrolled variables. We could not 
obtain details of the patients’ nutrition, including biochemical components and nutritional intake. The results are 
based on available data, which could not encompass all patients in this study, especially the outcomes and compli-
cations of enteral tube feeding. The outcomes and complications were evaluated on a numerical basis, and did not 
go through statistical analysis. Further statistical analysis could improve the power of the outcomes concerning 
enteral tube feeding among patient groups.
Nutrition is a crucial factor in supportive care of patients with mitochondrial disease. Enteral tube feeding 
could ameliorate growth failure and improve quality of life by relieving GI symptoms. Thus, the medical team 
should closely monitor and promptly manage symptoms indicating the need for enteral tube feeding as a part of 
systemic management.
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